後ECFA投資中國醫療生技之策略方向:
case study-Medical Investment

 

 

 

 

摘要:

Medical investment

 

創新思考,大規模搜尋網站,找到創新經營觀念與模式,創新產品、創新技術、創新原料、創新行銷組合、創新經營模式、創新之人才僱用方式、創新溝通方法等、隨時思考「創新方法」讓思想起飛

Creative thinking, sites to find innovative business concepts and modes, product, technology, materials and marketing approach, business modes, recruiting ways and communication methods in large scale, in this way, let your mind soar at any time with innovative methods

 

個案專討方向:

The cases study direction

 

1.    後ECFA有關醫院服務業:允許台灣服務提供者在大陸設立合資、合作醫院,以及在上海市、江蘇省、福建省、廣東省、海南省、沿海地區設立獨資醫院。

 

2. 目前生技服務業之發展現況之策略方向;並以80/20法則列出生技服務企業之經營模式及個別廠商,並找出標竿企業

    Current Biotechnology services' developing status and strategic direction, with 80/20rules listing business mode of biotech industry and individual manufacturers, and to identify the standard enterprise.

 

3.    未來CROCMOOEM廠商)之商機與契機及策略模式

    Business opportunities and strategies and modes.Future CRO and CMO (OEM

    manufacturers)

 

4.  如何將策略聯盟或策略合作夥伴之經營模式的核心概念與CROCMO相結合,形成創新經營模式。

    How to combine the key concept of strategic alliances or strategic partner mode and CRO, CMO to form the innovative business mode.

 

5.   評估CROCMO之企業,未來所可能產生的危機與商機

    Assessment CRO and the CMO business, the potential future crises and

    opportunities.

 

6.      SFDA之規範下,CROCMO,尤其CMO,其發展前景為何?委託者及被委託者

   (CROCMO),在SFDA之架構下,其發展前景為何?

       Under the regulation of SFDA, CRO and CMO, esp. CMO, what about their future

       development prospects? The trust and trustee (CRO and CMO), in the framework of  SFDA, what about their future?

 

7.      複合式醫療器材(Combination Product):含藥品之醫療器材EX:心臟血管支架

        steroid及玻尿酸或collagen與材料做結合,其定義為何?其發展前景為何?

        Compound medical equipment(Combination Product): medical equipment containing drugs EX: combine steroid and collagen or hyaluronic acid, what is definition and its future prospect?

 

8.     針對CROCMO有那些標竿企業

        Standard enterprise in view of CRO and CMO

 

9.     投資資本之法規及規定及外匯管制流向

        Regulations and capital investment requirements and the flow of foreign exchange controls

 

10.   各生技領域之企業或工業名錄;並說明如何利用及擷取資訊

         Biotechnology industry or enterprise directory;and on how to use and retrieve information.

 

11.   各領域之權威雜誌、名錄及網站;並說明如何利用及擷取資訊

         Authority magazines, directories and websites; and on how to use and retrieve information.

 

12.   GAP法規及技術雜誌、名錄及網站;並說明如何利用及擷取資訊

         GAP regulations and technical magazines, directories and websites, and how to take advantage  of and retrieve information.

 

13.   如何與娛樂產業相結合,以形成之企業競爭優勢

         How to combine with the entertainment industry to form a corporate competitive edge.

 

14.   公司對員工健康人個人保險之企業政策

         Enterprises'  employee health insurance policy

 

15.   保險公司與醫療機構+生技醫藥公司之合作策略:

         (1) 針對員工之健康保險(2)員工之養老保險形成新的事業模式

          Insurance companies and medical institutions + biotech companies Cooperation Strategy:

          (1) Health insurance for employees (2) Employees of the pension insurance  → a new career  mode.

 

16.    政府對企業保險公司之健康保險的策略及內容有何具體規範?

          What's the government's specific norm to enterprises'  health insurance's strategy and content?

 

17.    政府對養老保險的規範是否包含醫療保險?其有何具體規範?

          Whether the government's  regulation toward pension insurance including medical insurance? What's the detail regulation?

 

18.    企業保險公司與醫療機構&生技醫藥公司→形成創新模式之養老保險的政策方向

          Enterprises insurance companies and medical institutions & Biotech company → form the innovative endowment insurance policy direction.

 

19.     政府對企業保險公司所推出之健康保險、醫療保險、防癌保險、養老保險是否有明確之規範與方向及內容

           Whethet the government has clear regultaion to the healthy insurance ,medical insurance , anti-cancer insurance, endowment insurance ? And what's their direction and content?

 

20.     政府對公營與民營之健康保險政策、醫療保險的政策、養老保險政策,將影響生技與醫藥企業及醫療機構之發展

           Government's regulations to health insurance , medical insurance and endowment insurance's policy for public and private enterprises' and these will influence biotech and pharmaceutical enterprises' development.

 

21.     政府對「國家基本醫療保險」之政策內容及未來之發展趨勢,找出可以與發展相結合之「生技醫藥企業及醫療機構」之事業模式

             Government's "national basic medical insurance" policy content and the future development trends, identify trends which can be combines with the biotech companies and medical institutions'  business mode.

 

22.     處方藥品總支出,其中「國家基本醫療保險」之支出估多少%

           Total expenditure of Prescription drugs and what is the "national basic medical insurance"

            ratio?

 

23.   「國家基本醫療險」對「生技醫藥企業」之發展有多大影響?

            What's the National basic medical insurance's impact on the development of biotech pharama enterprises?

 

 

歡迎您留下您寶貴的意見粉絲專頁